No association between C-45T polymorphism in the Sp1 binding site of the promoter region of the cholecystokinin gene and alcoholism

被引:16
作者
Ishiguro, H
Saito, T
Shibuya, H
Toru, M
Arinami, T [1 ]
机构
[1] Univ Tsukuba, Inst Basic Med Sci, Dept Med Genet, Tsukuba, Ibaraki 3058575, Japan
[2] Tokyo Med & Dent Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan
[3] Sapporo Med Univ, Sapporo, Hokkaido, Japan
关键词
A10 dopamine neurons; restriction fragment length polymorphism; Japanese; genetics;
D O I
10.1016/S0165-1781(98)00127-9
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The activity of dopamine-containing neurons in the ventral tegmental area and nucleus accumbens may play a role in alcoholism. Cholecystokinin (CCK) co-exists in a large proportion of A10 dopamine neurons to exert some effect on dopamine-induced behavior. Recently, a C-45T polymorphism was discovered in the Spl binding site in the CCK gene promoter region. We investigated an association between the polymorphism and alcoholism in 209 Japanese DSM-III-R alcoholics and 113 Japanese control subjects. The patients and the control subjects had similar allele and genotype frequencies: the T allele frequencies were 0.27 in the patients and 0.28 in the control subjects and the CC, CT, and the TT genotype frequencies 0.53, 0.39, and 0.08 in the alcoholics and 0.53, 0.37, and 0.10 in the control subjects. Frequencies of clinical characteristics of Feighner's criteria for the lifetime diagnosis of alcoholism were not significantly different among the patient groups divided by the genotype. These findings indicate that the polymorphism has no major effect on the etiology of alcoholism. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:209 / 213
页数:5
相关论文
共 24 条
[1]  
*AM PSYCH ASS, 1987, DSM3R DIAGN STAT MAN
[2]  
BORENSTEIN M, 1997, POWER PRECISION
[3]   Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder [J].
Bowen, T ;
Norton, N ;
Jacobsen, NJO ;
Guy, C ;
Daniels, JK ;
Sanders, RD ;
Cardno, AG ;
Jones, LA ;
Murphy, KC ;
McGuffin, P ;
Craddock, N ;
O'Donovan, MC ;
Owen, MJ .
MOLECULAR PSYCHIATRY, 1998, 3 (01) :67-71
[4]  
Ciraulo AM, 1997, AM FAM PHYSICIAN, V56, P803
[5]   BIOLOGICAL ACTIONS OF CHOLECYSTOKININ [J].
CRAWLEY, JN ;
CORWIN, RL .
PEPTIDES, 1994, 15 (04) :731-755
[6]  
CRAWLEY JN, 1992, J NEUROSCI, V12, P3380
[7]   OPPOSITE EFFECTS OF CHOLECYSTOKININ OCTAPEPTIDE (CCK-8) AND TETRAPEPTIDE (CCK-4) AFTER INJECTION INTO THE CAUDAL PART OF THE NUCLEUS-ACCUMBENS OR INTO ITS ROSTRAL PART AND THE CEREBRAL-VENTRICLES [J].
DEWITTE, P ;
HEIDBREDER, C ;
ROQUES, B ;
VANDERHAEGHEN, JJ .
NEUROCHEMISTRY INTERNATIONAL, 1987, 10 (04) :473-479
[8]   CCK-B ANTAGONISTS EXHIBIT ANTIDEPRESSANT-LIKE EFFECTS AND POTENTIATE ENDOGENOUS ENKEPHALIN ANALGESIA - CORRELATION WITH IN-VIVO BINDING AFFINITIES AND BRAIN PENETRATION [J].
DURIEUX, C ;
DERRIEN, M ;
MALDONADO, R ;
VALVERDE, O ;
BLOMMAERT, A ;
FOURNIEZALUSKI, MC ;
ROQUES, BP .
CHOLECYSTOKININ, 1994, 713 :355-357
[9]   DIAGNOSTIC CRITERIA FOR USE IN PSYCHIATRIC RESEARCH [J].
FEIGHNER, JP ;
WOODRUFF, RA ;
WINOKUR, G ;
MUNOZ, R ;
ROBINS, E ;
GUZE, SB .
ARCHIVES OF GENERAL PSYCHIATRY, 1972, 26 (01) :57-&
[10]  
Hartmann PM, 1997, AM FAM PHYSICIAN, V55, P1877